Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Summary

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Timeline

Start

2023-05-02

Primary completion

2027-04-05

Completion

2027-04-05

Drugs

Indications